Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and autoimmune diseases, has reportedly secured USD 27 million in a Series C financing round. The round was led by YD Capital and saw participation from Jiashan County State-owned Assets Investment, Betta Pharma’s industry fund, Wedo Venture, and DT Capital Partners.
Investment to Accelerate Clinical Trials for DF-006 and DF-003
The funds raised will be directed towards clinical studies for DF-006, an oral ALPK1 agonist, and the advancement of DF-003 into a Phase I clinical trial. DF-006 has demonstrated its ability to effectively activate the innate immune system of the liver, leading to a robust immune response. With preclinical anti-HBV activity data already published and Phase I clinical evaluation completed, a global multicenter trial targeting patients with chronic HBV is set to be conducted.
DF-003: A Potential Treatment for ROSAH Syndrome
DF-003, another oral ALPK1 kinase inhibitor developed by Drug Farm, is expected to be used for the treatment of the rare genetic disease ROSAH syndrome, which is caused by ALPK1 mutations. The drug is anticipated to enter Phase I clinical trials in 2023.
Drug Farm’s Innovative Technologies
Founded in 2015, Drug Farm is equipped with IDInVivo Å, a technology based on transposons for gene screening and direct discovery of new drug targets in living animals with intact immune systems. Additionally, the company utilizes MedChem5, which employs deep learning technology for drug molecule design. These innovative technologies position Drug Farm at the forefront of biotech research and development.-Fineline Info & Tech
